Key facts
- Pentapharm’s last known valuation is $96.3M (May 2007).
- Notable investors include Orlando Capital.
- Status: Acquired/Merged (Operating Subsidiary).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Pentapharm
- ·The full record, as it builds
Funding rounds
No funding rounds for Pentapharm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pentapharm
Developer of active ingredients and system solutions intended to advance coagulation research and therapeutic development. The company develops and produces active ingredients and system services for niche applications in the context of human blood coagulation disorders.
- Sector
- Healthcare
- HQ
- Aesch, Switzerland
- Founded
- 1948
- Employees
- 120
- Website
- pentapharm.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Pentapharm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pentapharm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pentapharm in its N-PORT filings yet. We sweep new filings monthly.